A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis.

A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018 Feb 20;: Authors: Hirano A, Umeno J, Okamoto Y, Shibata H, Ogura Y, Moriyama T, Torisu T, Fujioka S, Fuyuno Y, Kawarabayasi Y, Matsumoto T, Kitazono T, Esaki M Abstract BACKGROUND AND AIM: The gut microbiota is suggested to play an important role in the pathogenesis of ulcerative colitis (UC). However, inter-individual and spatial variations hamper the identification of UC-related changes. We thus investigated paired mucosa-associated microbiota obtained from…

Read More

Crohn’s Disease associated Strictures.

Crohn’s Disease associated Strictures. J Gastroenterol Hepatol. 2018 Feb 10;: Authors: Wo WCP, Mourad F, Leong RWL Abstract Crohn’s disease (CD) is a chronic relapsing and remitting disease that can affect any segments of the gastrointestinal (GI) tract. More than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. Strictures can lead to intestinal obstruction, which is a common indication for surgery. Despite significant advances in the understanding of the pathogenesis of intestinal fibrostenosis, imaging and therapeutic armamentarium of CD, the risk…

Read More

Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis.

Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2018 Feb 10;: Authors: Dai C, Jiang M, Sun MJ, Cao Q Abstract OBJECTIVE: Fecal immunochemical test (FIT) is a promising marker for assessment of inflammatory bowel disease (IBD) activity. However, the utility of FIT for predicting mucosal healing (MH) of Ulcerative Colitis (UC) patients has yet to be clearly demonstrated. The objective of our study was to perform a diagnostic test accuracy test meta-analysis evaluating the diagnostic accuracy of FIT…

Read More

Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients.

Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients. J Gastroenterol Hepatol. 2018 Feb 06;: Authors: Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R Abstract BACKGROUND: The number of elderly patients with ulcerative colitis (UC) is increasing. Several new therapies for UC have improved patient outcomes. Leukocytapheresis (LCAP) is an extracorporeal therapy for UC. However, its efficacy and safety for elderly UC patients has not been reported. METHODS: We conducted a post hoc analysis…

Read More

Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?

Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? J Gastroenterol Hepatol. 2018 Jan;33(1):10-11 Authors: Rentsch C, Headon B, Ward MG, Gibson PR PMID: 29284080 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29284080?dopt=Abstract

Read More

Predicting Response after Infliximab Salvage in Acute Severe Ulcerative Colitis.

Predicting Response after Infliximab Salvage in Acute Severe Ulcerative Colitis. J Gastroenterol Hepatol. 2017 Dec 21;: Authors: Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, Sparrow MP, Connell WR, Moore GT, Radford-Smith G, Van Langenberg DR, De Cruz P Abstract OBJECTIVES: Acute severe ulcerative colitis (ASUC) is a medical emergency requiring prompt therapeutic intervention. Although Infliximab has been used as salvage therapy for over 15 years, clinical predictors of treatment success are lacking. We performed a retrospective analysis to identify factors that predict colectomy and may…

Read More

Combination of Increased Visceral Fat and Long Segment Involvement: Development and Validation of an updated imaging marker for differentiating Crohn’s Disease from Intestinal Tuberculosis.

Combination of Increased Visceral Fat and Long Segment Involvement: Development and Validation of an updated imaging marker for differentiating Crohn’s Disease from Intestinal Tuberculosis. J Gastroenterol Hepatol. 2017 Dec 04;: Authors: Kedia S, Madhusudhan KS, Sharma R, Bopanna S, Yadav DP, Goyal S, Jain S, Das P, Dattagupta S, Makharia G, Ahuja V Abstract BACKGROUND: Computed tomographic(CT) features(long segment, ileocaecal area involvement and lymph nodes>1cm) have demonstrated good specificity but poor sensitivity, while visceral to subcutaneous fat ratio on CT(VF/SC>0.63) has moderate sensitivity and specificity in differentiating Crohn’s disease(CD) and…

Read More

The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines.

Related Articles The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines. J Gastroenterol Hepatol. 2017 Nov 04;: Authors: Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M Abstract BACKGROUND AND AIM: New Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSC) in the world. Thiopurine use in Inflammatory Bowel Disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD…

Read More

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease.

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease. J Gastroenterol Hepatol. 2017 Oct 31;: Authors: Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T, ADJUST study group Abstract BACKGROUND AND AIM: There are few studies on the long-term efficacy of adalimumab treatment for patients with Crohn’s disease. We have conducted a large, multicenter, retrospective cohort study…

Read More

Association of CDKN2A/B with inflammatory bowel disease in Koreans.

Related Articles Association of CDKN2A/B with inflammatory bowel disease in Koreans. J Gastroenterol Hepatol. 2017 Oct 24;: Authors: Lee HS, Lee SB, Kim BM, Hong M, Jung S, Hong J, Baek J, Han B, Oh SH, Kim KM, Park SH, Yang SK, Ye BD, Song K Abstract BACKGROUND AND AIM: CDKN2A/B locus on 9p21 is reported to be associated with various diseases, including cancer, cardiovascular and inflammatory diseases. Significant down-regulation of CDKN2B-AS1 in inflamed colon tissue of IBD cases was reported in Europeans. This study aimed to confirm the suggestive…

Read More
<< Go Back